Skip to content
  1. Home
  2. News
  3. Reata Pharmaceuticals and Blackstone Life Sciences Announce $350M Strategic Investment

Reata Pharmaceuticals and Blackstone Life Sciences Announce $350M Strategic Investment

Deals & Cases
June 11, 2020

Vinson & Elkins served as co-counsel to Reata Pharmaceuticals, Inc. in connection with a $350 million royalty and equity investment in Reata led by funds managed by Blackstone Life Sciences to fund the development and potential commercialization of bardoxolone methyl, an investigational once-daily oral therapy being studied for chronic kidney disease in Alport syndrome, autosomal dominant polycystic kidney disease and other associated potential future indications.

The financing also includes a $50 million investment in 340,793 shares of Reata’s Class A common stock at $146.72 per share. Reata will receive the $350 million investment at closing, which is expected to occur on or before June 24, 2020.

The V&E team was led by partner Robert Kimball with assistance from senior associate Katherine Frank and associate Breanna Kelly.

About Vinson & Elkins
For more than a century, Vinson & Elkins has provided outstanding client service across important industries that drive the global economy. Built on a strong culture of collaboration across 12 offices worldwide, V&E lawyers are committed to excellence, offering clients decades of legal experience in handling transactions, investments, projects and disputes across the globe. Learn more by visiting www.velaw.com or follow us on Twitter @VinsonandElkins or connect with us on LinkedIn.

For more information, please speak with our media contacts.

Key Contacts